Infimab is a recombinant chimeric human-murine IgG1? monoclonal antibody, which binds to both soluble and trans membrane forms of the human tumor necrosis factor (TNF)a and inhibits the functional activity of TNFa.

Infimab consists of two heavy and two light chains covalently linked by disulfide bonds and has molecular weight of 149 kDa. Infimab™ has been approved for treatment of rheumatoid arthritis (RA), Crohn’s disease (CD), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis and ulcerative colitis (UC).

Infimab is available in 100 mg single use vials as sterile white lyophilized powder for intravenous infusion, to be reconstituted with 10 ml of sterile water for injection.